SCHEMBL6743871

SCHEMBL6743871

O=C(NC(CCSc1ccccc1)(C(=O)O)C(=O)O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.56
RAB9A P51151 7/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
RECQL P46063 1/20 0.56
HDAC1 Q13547 1/20 0.48
ALDH1A1 P00352 5/20 0.47
HPGD P15428 3/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6741449 0.83 NPC1 (0.48) NPC1RAB9ASMN1; SMN2RECQLALDH1A1
SCHEMBL11032619 0.74 POLB (0.44) SMN1; SMN2HDAC1ALDH1A1CYP1A2CYP3A4
SCHEMBL5411923 0.73 ALDH1A1 (0.54) NPC1RAB9ASMN1; SMN2RECQLHDAC1
SCHEMBL6914649 0.70 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2RECQLHDAC1
SCHEMBL6912874 0.70 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2RECQLHDAC1
SCHEMBL6912524 0.70 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2RECQLHDAC1
SCHEMBL8144106 0.68 RAB9A (1.00) NPC1RAB9ASMN1; SMN2RECQLHDAC1
Dibenzoylmethane SCHEMBL29013375 0.67 KMT2A (0.63) NPC1RAB9ASMN1; SMN2RECQLHDAC1
Hydrochloric Acid SCHEMBL8144383 0.67 RAB9A (0.96) NPC1RAB9ASMN1; SMN2RECQLHDAC1
SCHEMBL10616144 0.67 HDAC3 (0.54) NPC1RAB9ASMN1; SMN2HDAC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed
EP-1212302-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-06-12 EP disclosed
WO-2001019796-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE NPC1 45/4885RAB9A 401/4885SMN1; SMN2 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.